Compare Gartner Inc (IT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Johnson & Johnson — how do they compare? Gartner Inc trades at $181.01 (market cap $11.83B), while Johnson & Johnson trades at $259.69 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 52.9× Gartner Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| IT | JNJ | |
|---|---|---|
Market Cap | $11.83B | $626.09B |
Sector | Technology | Health |
52-Week High | $264.09 | $267.24 |
52-Week Low | $125.68 | $172.78 |
Enterprise Value | $13.57B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.09, down 4.18% today, following a strong earnings beat in Q2 2026 with EPS of $4.37 versus $3.76 expected. The stock shows a bullish technical trend but trades above the consensus price target of $172.80. Recent news highlights a shareholder investigation and raised full-year EPS guidance, creating mixed sentiment amid strong profitability metrics like a 69.63% gross margin and 113.58% ROE.
The outlook is cautiously optimistic given earnings momentum and valuation discounts, but risks include consulting segment weakness, negative net cash flow trends, and the fiduciary investigation. Upside depends on sustained execution against guidance, while downside could stem from growth deceleration or legal overhangs.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
